WATERTOWN, Mass.--(BUSINESS WIRE)--Panacos Pharmaceuticals, Inc. (Nasdaq:PANC), a biotechnology company dedicated to developing the next generation of antiviral therapeutic products, today announced that Scott McCallister, M.D. has joined the Company as Chief Medical Officer. Dr. McCallister will be responsible for medical affairs and will spearhead the Company’s Phase 3 development efforts for bevirimat. He will report to Graham Allaway, Ph.D., Panacos’ President and COO.
